3281:TSEGLP J-REIT Analysis
Data as of 2026-06-26 - not real-time
₩9,880.00
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Price action is firmly under the 20‑day (13,942), 50‑day (16,788) and 200‑day (18,188) SMAs, with the current market price of 9,880 KRW sitting just above the identified support at 9,650 KRW and far below the resistance of 17,710 KRW. The RSI of 21.4 signals oversold conditions, yet the bearish MACD histogram (-385) and a clear bearish trend direction reinforce downside pressure, compounded by a high 30‑day volatility of 68% and a recent max drawdown of -63%.
Fundamentally, Lunit reports a solid revenue growth of 24.7% to 87.9 B KRW, but this is offset by a crushing operating margin of -56.8% and a profit margin of -76.4%, resulting in negative EBITDA of -65.4 B KRW and free cash flow of -92.8 B KRW. The balance sheet is strained with total debt of 147.9 B KRW against cash of 41.0 B KRW, yielding a debt‑to‑equity ratio of 118.5 and negative ROE/ROA. Valuation metrics show a price‑to‑sales of 8.36 and an implied upside of ~21% versus the target price of 12,000 KRW, but the lack of earnings (PE 0) and zero dividend further heighten risk. The market sentiment is currently in an "Extreme Greed" phase (Fear & Greed Index 85.36), which may be inflating price expectations despite the underlying financial weakness.
Fundamentally, Lunit reports a solid revenue growth of 24.7% to 87.9 B KRW, but this is offset by a crushing operating margin of -56.8% and a profit margin of -76.4%, resulting in negative EBITDA of -65.4 B KRW and free cash flow of -92.8 B KRW. The balance sheet is strained with total debt of 147.9 B KRW against cash of 41.0 B KRW, yielding a debt‑to‑equity ratio of 118.5 and negative ROE/ROA. Valuation metrics show a price‑to‑sales of 8.36 and an implied upside of ~21% versus the target price of 12,000 KRW, but the lack of earnings (PE 0) and zero dividend further heighten risk. The market sentiment is currently in an "Extreme Greed" phase (Fear & Greed Index 85.36), which may be inflating price expectations despite the underlying financial weakness.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 8/10
Key Factors
- price below all major moving averages
- bearish MACD and trend direction
- high debt load and negative cash flow
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- strong revenue growth potential
- oversold RSI suggests possible technical bounce
- target price implies ~21% upside
Long Term
> 3 yearsNeutral
Model confidence: 4/10
Key Factors
- uncertain regulatory approvals for AI medical tools
- persistent cash burn and leverage
- structural growth in health information services
Key Metrics & Analysis
Technical Analysis
TrendBearish
RSI21.4
Support₩9,650.00
Resistance₩17,710.00
MA 20₩13,942.00
MA 50₩16,787.60
MA 200₩18,188.42
MACDBearish
VolumeDecreasing
Fear & Greed Index85.36
Risk Assessment
Beta1.07
Volatility67.89%
Sector RiskHigh
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.